天士力上半年分红率40.50%，为投资者创造长期价值

Group 1 - The traditional Chinese medicine (TCM) industry faced pressure in the first half of 2025, with the TCM index recording a decline of 0.79%, while Tianshili (600535) stock price increased by 9.7%, indicating market optimism about the company's future performance [1][2] - Tianshili reported a net profit attributable to shareholders of 775 million yuan in the first half of 2025, representing a year-on-year growth of 16.97%, with steady improvement in operational performance and quality [1][2] - The company plans to distribute a cash dividend of 2.1 yuan per 10 shares (tax included) to all shareholders, with a dividend payout ratio of 40.50% [1][3] Group 2 - The pharmaceutical manufacturing industry in China saw a revenue of 1,227.52 billion yuan in the first half of 2025, a year-on-year decrease of 1.2%, and total profits of 176.69 billion yuan, down 2.8% [2] - Tianshili's revenue for the first half of 2025 was 4.288 billion yuan, with pharmaceutical industrial revenue stable at 3.879 billion yuan and commercial revenue at 386 million yuan [2] - The company's debt-to-asset ratio decreased from 19.13% at the beginning of the year to 18.43% by the end of the reporting period, a reduction of 0.7 percentage points [2] Group 3 - Tianshili underwent a change in controlling shareholder to China Resources Sanjiu (000999) and completed the restructuring of its board of directors and supervisory board [4] - The company is actively implementing the management philosophy of China Resources, enhancing financial, human resources, and operational management integration, and initiating a "Fifteen Five" strategic planning process [4][5] - The company aims to enhance marketing collaboration with China Resources, integrating resources to improve market share and address distribution challenges in certain markets [4][5]